Spinogenix

Spinogenix has FDA clearance for an IND application, and enrollment is open at a U.S. site for a Phase 2 clinical trial of SPG302, a synaptic regenerative therapy being developed for schizophrenia.

NeurologyLive featured Spinogenix Chief Development Officer Dr. Sharron Gargosky at AAIC2025 in Toronto, discussing Phase 2a study findings for SPG302 in participants with mild to moderate Alzheimer’s disease in Australia.

Spinogenix is developing synaptic regenerative treatments for ALS and other neurodegenerative diseases. An interview features founder and CEO Dr. Stella Sarraf and board member Steve Young.

Dr. Craig Erickson has conducted translational research in neurodevelopmental disorders for twenty years. He leads a translational medicine program at Cincinnati Children’s Hospital Medical Center focused on detecting treatment-related brain target engagement in individual patients.

Jerre Stead was Executive Chairman and CEO of Clarivate plc from June 2019 until retiring in October 2022 and CEO of Churchill Capital Corp until its May 2019 merger with Clarivate.

Dr. Merit Cudkowicz chairs the Massachusetts General Hospital Department of Neurology, directs the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School in Boston.

Dr. Mervyn Turner has nearly 35 years of experience in pharmaceutical drug discovery, research and development, licensing, business development, and emerging markets strategy. He operates MJ Turner Consulting and spent 27 years at Merck & Co.